↓ Skip to main content

Dove Medical Press

Article Metrics

Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety

Overview of attention for article published in Drug Design, Development and Therapy, November 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

policy
1 policy source
twitter
10 tweeters

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
35 Mendeley
Title
Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety
Published in
Drug Design, Development and Therapy, November 2014
DOI 10.2147/dddt.s73428
Pubmed ID
Authors

Xingguo Zhang, Zhihai Yang, Xingguang Liang, Kuifen Ma, Dongsheng Hong, Shuyin Han

Abstract

Anakinra is the first interleukin-1 inhibitor to be used in clinical practice, and recent evidence showed that interleukin-1 plays a pivotal role in the pathogenesis of adult-onset Still disease (AoSD). However, data concerning efficacy with anakinra use in different clinical trials has not been evaluated, and the overall remission of AoSD with anakinra treatment has not been well defined.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 35 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 17%
Student > Postgraduate 5 14%
Student > Master 4 11%
Student > Bachelor 3 9%
Student > Ph. D. Student 3 9%
Other 6 17%
Unknown 8 23%
Readers by discipline Count As %
Medicine and Dentistry 12 34%
Pharmacology, Toxicology and Pharmaceutical Science 4 11%
Agricultural and Biological Sciences 3 9%
Neuroscience 3 9%
Immunology and Microbiology 1 3%
Other 1 3%
Unknown 11 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2022.
All research outputs
#3,211,820
of 22,491,736 outputs
Outputs from Drug Design, Development and Therapy
#187
of 2,065 outputs
Outputs of similar age
#39,563
of 253,989 outputs
Outputs of similar age from Drug Design, Development and Therapy
#5
of 19 outputs
Altmetric has tracked 22,491,736 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,065 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,989 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.